Featured Research

from universities, journals, and other organizations

Statin use is linked to increased risk of developing diabetes, warn researchers

Date:
May 23, 2013
Source:
BMJ-British Medical Journal
Summary:
Treatment with high potency statins (especially atorvastatin and simvastatin) may increase the risk of developing diabetes, suggests a new article.

Treatment with high potency statins (especially atorvastatin and simvastatin) may increase the risk of developing diabetes, suggests a new article.

Statins are among the most widely prescribed medications for the prevention of cardiovascular events. Although tolerated well, an association with new-onset diabetes has recently been suggested. One trial suggested a 27% increased risk of diabetes with rosuvastatin whereas another suggested patients taking pravastatin benefitted from a 30% lower risk.

As there is limited data on this subject, researchers from Canada carried out a population-based study on 1.5 million residents in Ontario, Canada to examine the association between individual statin use and new-onset diabetes.

All patients were aged 66 and over and started statin therapy between 1997 and 2010. The median age was 73 years. Follow up ended either at the end of 2010 or a maximum of five years following the initiation of statins, whichever came first. The primary outcome was incident diabetes.

Data were taken from the Ontario Drug Benefit database, the Canadian Institute for Health Information Discharge Abstract Database and the Ontario Diabetes Database. Statins included in the study were: fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin and rosuvastatin.

All studies used pravastatin-treated patients as the comparison group as this has been shown to have favourable effects on newly diagnosed diabetes in animal models and clinical trials.

471,250 patients were identified with no history of diabetes and who were newly treated with a statin. 54% were women. Atorvastatin accounted for more than half of all new statin prescriptions followed by rosuvastatin, simvastatin, pravastatin, lovastatin and fluvastatin.

The overall risk of developing diabetes was low but this risk was increased among some patients taking statins. Between 162 and 407 patients would have to be treated with the various statins for one extra patient to develop diabetes. Patients treated with atorvastatin were found to have a 22% increased risk of new-onset diabetes, rosuvastatin an 18% increased risk and simvastatin a 10% increased risk, relative to pravastatin. In contrast, patients treated with fluvastatin were at a 5% decreased risk and lovastatin a 1% decreased risk.

The event rate was highest for atorvastatin (30 outcomes per 1000 person-years) and rosuvastatin (34 per 1000 person-years). Simvastatin accounted for 26 outcomes per 1000 person-years with both fluvastatin and lovastatin at 21 outcomes per 1000 person-years.

The researchers found consistent results in analyses examining the use of statins for primary prevention (when those without established disease are treated) and secondary prevention (when those with established disease are treated). Their findings also suggest that older patients are at an increased risk regardless of dose for atorvastatin and simvastatin or whether therapy is used for primary or secondary prevention.

The researchers say several factors may explain the increased risk of new-onset diabetes among patients receiving certain statins including impaired insulin secretion and inhibited insulin release.

In conclusion, the researchers say clinicians should consider risk when contemplating statin therapy. They add that "preferential use of pravastatin, and potentially fluvastatin […] may be warranted" and that pravastatin may even be beneficial to patients at high risk of diabetes.

In an accompanying editorial, doctors from the University of Turku in Finland say that "the overall benefit of statins still clearly outweighs the potential risk of incident diabetes." They conclude that as statins have been shown to reduce cardiovascular events in patients, they "play an important role in treatment."


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Journal References:

  1. A. A. Carter, T. Gomes, X. Camacho, D. N. Juurlink, B. R. Shah, M. M. Mamdani. Risk of incident diabetes among patients treated with statins: population based study. BMJ, 2013; 346 (may23 4): f2610 DOI: 10.1136/bmj.f2610
  2. R. Huupponen, J. Viikari. Statins and the risk of developing diabetes. BMJ, 2013; 346 (may23 5): f3156 DOI: 10.1136/bmj.f3156

Cite This Page:

BMJ-British Medical Journal. "Statin use is linked to increased risk of developing diabetes, warn researchers." ScienceDaily. ScienceDaily, 23 May 2013. <www.sciencedaily.com/releases/2013/05/130523223823.htm>.
BMJ-British Medical Journal. (2013, May 23). Statin use is linked to increased risk of developing diabetes, warn researchers. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/05/130523223823.htm
BMJ-British Medical Journal. "Statin use is linked to increased risk of developing diabetes, warn researchers." ScienceDaily. www.sciencedaily.com/releases/2013/05/130523223823.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins